secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clearside Biomedical, Inc. (CLSDQ)
CIK:        0001539029
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0000950170-24-095451
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clearside Biomedical Q2 net loss narrows to $7.6M; Phase 2b wet AMD trial on track for late Q3 data
--------------------------------------------------------------------------------

- Net loss of $7.6M ($0.10/sh) vs $9.1M ($0.15/sh) in Q2 2023; license revenue $90,000.
- Phase 2b ODYSSEY topline data for wet AMD expected late Q3 2024; no drug-related SAEs observed.
- Cash and investments total $29.4M; company expects operations funded into Q3 2025.
- Arctic Vision reports positive Phase 3 ARCATUS results; NDAs accepted in Australia and Singapore.
- Tony Gibney appointed to Board; Dr. Glenn Yiu added to Scientific Advisory Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1539029/000095017024095451/0000950170-24-095451-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1539029/000095017024095451/clsd-20240812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-095451

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer